Search Results - "Pulkstenis, E."

An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C by Patel, K., Benhamou, Y., Yoshida, E. M., Kaita, K. D., Zeuzem, S., Torbenson, M., Pulkstenis, E., Subramanian, G. M., McHutchison, J. G.

“…Noninvasive markers that accurately follow changes in fibrosis may provide alternatives to liver biopsy for assessment of histological endpoints of antiviral…”
Get full text

1084 INDEPENDENT VALIDATION OF THE SAFE BIOPSY ALGORITHM: ANALYSIS OF THE ACHIEVE COHORTS by Thompson, A, Clark, P, Tillmann, H, Torbenson, M, Pulkstenis, E, Subramanian, G.M, McHutchison, J, Patel, K

Get full text

287 EVALUATING VIROLOGIC RESPONSE WITHIN 2–4 WEEKS HAS HIGH POSITIVE/NEGATIVE PREDICTIVE VALUES FOR SUSTAINED VIROLOGIC RESPONSE IN PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C DURING TREATMENT by Neumann, A, Shiffman, M, Ferenci, P, Foster, G, Yoshida, E, Pianko, S, Sulkowski, M, Zeuzem, S, Benhamou, Y, Nelson, D, McHutchison, J, Pulkstenis, E, Subramanian, G

Get full text

416 LONGITUDINAL PROSPECTIVE COMPARISON OF FIBROSURE AND TRANSIENT ELASTOGRAPHY IN RELATION TO VIROLOGIC RESPONSE: A SUBSTUDY OF THE PHASE 3 ALBINTERFERON ALFA-2B TRIALS by Patel, K, Friedrich-Rust, M, Torbenson, M, Zhu, Y, Pulkstenis, E, Subramanian, G, McHutchison, J, Nelson, D, Sulkowski, M, Benhamou, Y, Zeuzem, S

Get full text

818 VIRAL KINETICS AND PHARMACODYNAMICS OF ALBINTERFERON ALFA-2B IN INTERFERON TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1, CHRONIC HEPATITIS C by Neumann, A.U, Rozenberg, L, Bain, V.G, McHutchison, J.G, Pulkstenis, E, Subramanian, G.M

Get full text

1042 EFFICACY AND SAFETY RESULTS OF ALBINTERFERON ALFA-2B IN COMBINATION WITH RIBAVIRIN IN INTERFERON-ALFA TREATMENT NAIVE PATIENTS WITH GENOTYPE 2 OR 3 CHRONIC HEPATITIS C by Nelson, D, Benhamou, Y, Chuang, W.L, Lawitz, E, Flisiak, R, Rodriguez-Torres, M, Bain, V, Patel, K, Cronin, P.W, Pulkstenis, E, Subramanian, G.M, McHutchison, J.G

Get full text

1041 EFFICACY AND SAFETY OF ALBINTERFERON ALFA-2B IN COMBINATION WITH RIBAVIRIN IN TREATMENT- NAIVE, CHRONIC HEPATITIS C GENOTYPE 1 (CHC G1) PATIENTS by Zeuzem, S, Sulkowski, M, Lawitz, E, Rustgi, V, Lurie, Y, Grigorescu, M, Muir, A, Cronin, P, Pulkstenis, E, Subramanian, M, McHutchison, J

Get full text

817 POSITIVE PREDICTIVE VALUE OF EARLY ANTIVIRAL RESPONSE PROFILE WITH ALBINTERFERON ALFA-2B IN IFN-NAIVE PATIENTS WITH GENOTYPE 1, CHRONIC HEPATITIS C by Neumann, A.U, Zeuzem, S, Yoshida, E, Benhamou, Y, Pianko, S, McHutchison, J.G, Pulkstenis, E, Subramanian, G.M

Get full text

819 HEALTH-RELATED QUALITY OF LIFE (HRQOL) WITH ALBINTERFERON ALFA-2B PLUS RIBAVIRIN IN IFN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C by Pianko, S, Yoshida, E, Zeuzem, S, Benhamou, Y, Bain, V, Pulkstenis, E, McHutchison, J.G, Subramanian, G.M

Get full text

834 ANTIVIRAL ACTIVITY AND CHANGES IN B-LYMPHOCYTE STIMULATOR PROTEIN LEVELS DURING TREATMENT WITH ALBINTERFERON ALFA-2B/RIBAVIRIN IN PRIOR INTERFERON-THERAPY NONRESPONDERS by Rustgi, V, Nelson, D, Balan, V, Sulkowski, M, McHutchison, J.G, Fiscella, M, Cronin, P, Pulkstenis, E, Subramanian, G.M

Get full text

[624] ALBUMIN INTERFERON ALFA-2b DOSED AT Q2W OR Q4W INTERVALS DEMONSTRATES COMPARABLE WEEK 12 EFFICACY RESPONSE IN IFN NAIVE, GENOTYPE-1 RAPID VIRAL RESPONDERS by Neumann, A.U, Rozenberg, L, Zeuzem, S, Benhamou, Y, McHutchison, J, Pulkstenis, E, Subramanian, M

Get full text

[779] ANTIVIRAL RESPONSE AT WEEK 12 FOLLOWING COMPLETION OF TREATMENT WITH ALBINTERFERON a-2b PLUS RIBAVIRIN IN GENOTYPE 1, IFN-NAIVE, CHRONIC HEPATITIS C PATIENTS by Zeuzem, S, Benhamou, Y, Bain, V, Shouval, D, Pianko, S, Flisiak, R, Grigorescu, M, Rehak, V, Yoshida, E, Kaita, K, Cronin, P, Pulkstenis, E, Subramanian, M, McHutchison, J

Get full text

[9] COMPARABLE ANTIVIRAL RESPONSE RATES WITH ALBUMIN INTERFERON ALFA-2B DOSED AT Q2W OR Q4W INTERVALS IN NAIVE SUBJECTS WITH GENOTYPE 2 OR 3 CHRONIC HEPATITIS C by Bain, V.G, Marotta, P, Kaita, K, Yoshida, E, Swain, M, Bailey, R, Neumann, A, Cronin, P, McHutchison, J, Pulkstenis, E, Subramanian, M

Get full text

Mixed Effects Logistic Regression Models for Longitudinal Binary Response Data with Informative Drop-Out by Thomas R. Ten Have, Kunselman, Allen R., Pulkstenis, Erik P., Landis, J. Richard

“…A shared parameter model with logistic link is presented for longitudinal binary response data to accommodate informative drop-out. The model consists of…”
Get full text

Estimation of mean quality adjusted survival time by Shen, L. Z., Pulkstenis, E., Hoseyni, M.

“…In clinical studies, we often consider not only patients' survival time, but also their quality of life. Quality adjusted life years (QALY) is an integrated…”
Get full text

Goodness-of-fit tests for ordinal response regression models by Pulkstenis, Erik, Robinson, Timothy J.

“…It is well documented that the commonly used Pearson chi‐square and deviance statistics are not adequate for assessing goodness‐of‐fit in logistic regression…”
Get full text

Two goodness-of-fit tests for logistic regression models with continuous covariates by Pulkstenis, Erik, Robinson, Timothy J.

“…Assessing goodness‐of‐fit in logistic regression models can be problematic, in that commonly used deviance or Pearson chi‐square statistics do not have…”
Get full text

Model for the Analysis of Binary Longitudinal Pain Data Subject to Informative Dropout through Remedication by Pulkstenis, Erik P., Ten Have, Thomas R., Landis, J. Richard

“…We address the problem of accounting for informative dropout in the form of rescue medication when comparing pain relievers with respect to longitudinal binary…”
Get full text

A mixed effects model for the analysis of ordinal longitudinal pain data subject to informative drop-out by Pulkstenis, Erik, Ten Have, Thomas R., Landis, J. Richard

“…We extend the model of Pulkstenis et al. that models binary longitudinal data, subject to informative drop‐out through remedication, to the ordinal response…”
Get full text

CO 7-Réponse anti-virale de l’albumine interféron alfa-2B en association A la ribavirine chez les malades infectés par le VHC de génotype 1 naïfs de traitement anti-VHC by Benhamou, Y., Bourlière, M., Hézode, C., Barange, K., Causse, X., Bronowicki, J.P., Poupon, R., Tran, A., Couzigou, P., Marcellin, P., Trépo, C., Zarski, J.P., Calès, P., Mathurin, P., Pol, S., Pulkstenis, E., Subramanian, M.

Get full text